subscribeSubscribe
price-trendAsk Us
Tarsus Q1 2024 Results, Business Achievements

Tarsus Q1 2024 Results, Business Achievements
GLOBENEWSWIRE
08 May 2024
Share Share
Tarsus Introduces Mite Party Campaign for XDEMVY

Tarsus Introduces Mite Party Campaign for XDEMVY
GLOBENEWSWIRE
05 Mar 2024
Share Share
Tarsus Announces Positive Topline Results from Carpo

Tarsus Announces Positive Topline Results from Carpo
GLOBENEWSWIRE
22 Feb 2024
Share Share
Now Available-XDEMVY, First and Only Approved Treatment for Demodex Blepharitis

Now Available-XDEMVY, First and Only Approved Treatment for Demodex Blepharitis
GLOBENEWSWIRE
24 Aug 2023
Share Share
FDA clears Tarsus` Xdemvy as first treatment for common eyelid disease

FDA clears Tarsus` Xdemvy as first treatment for common eyelid disease
Zoey Becker FIERCE PHARMA
26 Jul 2023
Share Share
Tarsus launches ‘Look at the Lids’ campaign for painful eyelid condition

Tarsus launches ‘Look at the Lids’ campaign for painful eyelid condition
Ben Adams FIERCEPHARMA
30 Sep 2022
Share Share
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment
GLOBENEWSWIRE
07 Sep 2022
Share Share
Eyelid mites no match for Tarsus eye drop, teeing up FDA push

Eyelid mites no match for Tarsus eye drop, teeing up FDA push
Max Bayer FIERCEBIOTECH
02 May 2022
Share Share